The Prolaris Test

Prolaris is a prognostic test developed by Myriad Genetic Laboratories, which directly measures tumor cell growth characteristics for stratifying the risk of disease progression in prostate cancer patients. The 46-gene expression signature includes cell cycle progression genes selected based upon correlation with prostate tumor cell proliferation:

  • low gene expression associated with a low risk of disease progression
  • high gene expression associated with disease progression

Prolaris testing combines traditional risk factors with a molecular assessment of the aggressiveness of an individual patient’s cancer to deliver a more informed risk assessment. Click here to learn more about Prolaris.